Novavax (NVAX) News Today

Novavax, Inc. (NASDAQ: NVAX) appears to be getting a lift from a wave of more optimistic analyst commentary, even though the stock has also seen some recent market weakness. Zacks Research upgraded the stock from hold to strong-buy and raised earnings estimates across multiple future periods, suggesting improving profitability expectations for the biotech company. That kind of upward revision can support the share price because investors often use analyst forecasts as a signal that fundamentals are getting better.

• Positive Sentiment: Zacks Research upgraded Novavax to Strong-Buy, which is a favorable rating change that can boost investor sentiment. Zacks.com
• Positive Sentiment: Analysts raised Novavax earnings estimates for Q1 2027, Q2 2027, Q3 2027, Q4 2027, FY2027, and FY2028, indicating a more bullish outlook for future profitability. MarketBeat NVAX
• Neutral Sentiment: Novavax remains a high-volatility biotech name with shares trading near recent moving averages, so sentiment shifts from analysts can have an outsized effect on the stock. MarketBeat NVAX
• Negative Sentiment: Recent market coverage noted that Novavax had a larger drop than the general market in the prior session, showing the shares have still faced near-term pressure. Yahoo Finance

Overall, NVAX looks supported today by the analyst upgrade and higher earnings forecasts, which outweigh the softer short-term trading action.